- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05790200
Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma
March 27, 2023 updated by: kunyu yang, Wuhan Union Hospital, China
A Phase II Clinical Study of Cadonilimab (AK104) Combined With Chemotherapy in the Treatment of PD-1 Inhibitor Resistant Nasopharyngeal Carcinoma
This study is a phase II clinical study of Cadonilimab (AK104) combined with chemotherapy in the treatment of PD-1 inhibitor-resistant nasopharyngeal carcinoma.
Study Overview
Detailed Description
The purpose is to evaluate the safety and effectiveness of Cadonilimab combined with chemotherapy in the treatment of PD-1 inhibitor-resistant nasopharyngeal carcinoma as the second line and above.
This study is a single-arm, phase II clinical study.
It is planned to enroll about 30 patients with PD-1 inhibitor resistant nasopharyngeal carcinoma.
PD-Ll CPS (<50% vs>50%, subjects whose PD-Ll expression could not be evaluated were classified as<50%) was used as the stratification factor.
The study will set up a safety induction period.
It is planned to enroll about 6 PD-1 inhibitor resistant subjects first, and the researchers will conduct a preliminary safety assessment.
If the safety and tolerability are good, and the preliminary curative effect signal is observed, it will enter the extended group period.
When about 15 subjects are selected, effectiveness analysis will be carried out.
If 6 of the 15 subjects with severe side effects can not tolerate, the researcher may stop the group of subjects after discussion.
In case of poor safety, the researcher decided to revise or stop the study after discussion.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yang Kunyu, doctor
- Phone Number: 13995595360
- Email: yangkunyu@hust.edu.cn
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430000
- Recruiting
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contact:
- Yang Kunyu, doctor
- Phone Number: 13995595360
- Email: yangkunyu@hust.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The age at the time of enrollment is more than 18 years old and less than 75 years old, both male and female.
- The Eastern Cancer Cooperation Organization (ECOG) physical fitness score was 0 or 1.
- The expected survival period is more than 3 months.
- Nasopharyngeal carcinoma confirmed by histology or cytology.
- The subject has previously received treatment with PD-1 inhibitor and failed without indication of radical local treatment.
According to the evaluation standard of curative effect of solid tumor, RECIST v l L At least one measurable lesion.
Exclusion Criteria:
- Except for nasopharyngeal carcinoma, the subjects had other malignant tumors within 2 years before enrollment. Subjects with other tumors that have been cured by local treatment, such as basal or cutaneous squamous cell carcinoma, superficial bladder cancer, cervical or breast cancer in situ, are not excluded.
- He participated in the treatment of experimental drugs within 4 weeks before the first study administration.
- Patients with active autoimmune diseases that require systematic treatment in the past two years (such as the use of disease improvement drugs, corticosteroids, immunosuppressive therapy), and replacement therapy (such as thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency) are not considered as a systemic treatment.
- Have a history of immune deficiency; HIV antibody test positive; At present, systemic corticosteroids or other immunosuppressants are being used for a long time.
- Active tuberculosis (TB) is known. Subjects suspected of active TB should be excluded from active TB.
- The history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation are known.
- The untreated active hepatitis B subjects (HBsAg positive and HBV-DNA more than 1000 copies/ml (200 IU/ml) or higher than the lower detection limit, whichever is higher) are required to receive anti hepatitis B virus treatment during the study treatment period; Active hepatitis C subjects (HCV antibody positive and HCV-RNA level higher than the lower limit of detection).
- Major surgical operation or serious injury occurred within 30 days before the first administration, or major surgical operation planner (determined by the researcher) within 30 days after the first administration; Minor local operations (excluding central venous catheterization via peripheral vein puncture) were performed within 3 days before the first administration.
- There is central nervous system metastasis.
- There are currently uncontrolled concomitant diseases, including but not limited to symptomatic congestive heart failure (grade 2 and above determined according to the functional classification of the New York Heart Association), unstable angina pectoris, acute myocardial ischemia, poorly controlled arrhythmia, decompensated liver cirrhosis, nephrotic syndrome, uncontrolled metabolic disorder, severe active peptic ulcer disease or gastritis, Mental illness/social condition that may limit the subject's compliance with the research requirements or affect the subject's ability to provide written informed consent.
- There was a history of myocarditis, cardiomyopathy and malignant arrhythmia in the past. Unstable angina pectoris, congestive heart failure or vascular disease (such as aortic aneurysm or peripheral venous thrombosis requiring surgical repair) that needs hospitalization within 12 months before the first administration of the drug, or other cardiac damage that may affect the safety evaluation of the study drug (such as poorly controlled arrhythmia, myocardial infarction or ischemia); There is a history of esophageal and gastric varices, serious ulcer, wound healing, gastrointestinal perforation, abdominal pain, gastrointestinal obstruction, abdominal abscess or acute gastrointestinal bleeding within 6 months before the first administration; Any arterial thromboembolic event occurred within 6 months before the first administration, including venous thromboembolic generation of NC I CTCAE 5.0 grade 3 and above, transient ischemic attack, cerebrovascular accident, hypertensive crisis or hypertensive encephalopathy; Acute exacerbation of chronic obstructive pulmonary disease occurred within 1 month before the first administration; There is currently hypertension and after treatment with oral antihypertensive drugs, the systolic blood pressure is more than 160 mmHg or the diastolic blood pressure is less than 100 mmHg.
- Have a history of severe bleeding tendency or coagulation dysfunction; One month before the first administration, there were blood symptoms with significant clinical significance, including but not limited to gastrointestinal bleeding, hemoptysis, screening imaging showed that the tumor wrapped around important blood vessels or had obvious necrosis and cavity, and the researcher believed that participating in the study might cause bleeding risk;
- The toxicity of previous anti-tumor treatment has not been relieved, which is defined as that the toxicity has not returned to the level 0 or 1 of NC l CTCAE 5.0, or the level specified in the inclusion/exclusion criteria, except for the sequelae of hair loss and previous lead treatment related neurotoxicity. Subjects (such as hearing loss) who have irreversible toxicity and are not expected to worsen after administration of the study drug may be included in the study after consultation with the medical examiner. Subjects with long-term toxicity caused by radiotherapy that cannot be recovered according to the judgment of the researcher may be included in the study after consultation with the medical supervisor.
- The live vaccine was vaccinated within 30 days before the first administration, or was planned to be vaccinated during the study period.
- Known allergy to any component of any study drug; A history of severe hypersensitivity to other monoclonal antibodies is known.
- Known history of mental illness, drug abuse, alcohol or drug abuse.
- Pregnant or lactating women.
- Any previous or current disease, treatment, or laboratory test abnormality may confuse the results of the study, affect the full participation of the subject in the study, or participation in the study may not be in the best interests of the subject.
- Local or systemic diseases caused by non-malignant tumors, or diseases or symptoms secondary to tumors, which can lead to higher medical risk and/or uncertainty of survival evaluation, such as tumor-like leukemia reaction (white blood cell count>20 X 109/L or cachexia performance (such as known weight loss of more than 10% in the 3 months before screening), etc
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cadonilimab (AK104) combined with chemotherapy
Cadonilimab (200 mg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy, Q3W, 4-6 cycles), every 3 weeks (21 days) is a treatment cycle
|
Cadonilimab (200 mg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy, Q3W, 4-6 cycles), every 3 weeks (21 days) is a treatment cycle.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Event(AE)
Time Frame: From randomization to the end of the study,the evaluation lasts for 24 months
|
The type, frequency, severity, timing, seriousness, and relationship to study therapyclinical significance
|
From randomization to the end of the study,the evaluation lasts for 24 months
|
Objective Response Rate,ORR
Time Frame: The last subject completes at least 24 weeks of follow-up (or disease progression)
|
The proportion of patients whose tumor volume is reduced to 30% and can be maintained for more than 4 weeks,Based on RECIST v i I Assessed ORR
|
The last subject completes at least 24 weeks of follow-up (or disease progression)
|
Progression-free survival,PFS
Time Frame: The last subject completes at least 24 weeks of follow-up (or disease progression)
|
The time from the beginning of the patient's treatment to the disease progression or death for any reason.Based on RECIST v i I Assessed PFS
|
The last subject completes at least 24 weeks of follow-up (or disease progression)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival,OS
Time Frame: 3 years
|
The time from the patient receiving treatment to the death of the patient for any reason,OS evaluated according to RECIST vi.
I
|
3 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to progress,TTP
Time Frame: The last subject completes at least 24 weeks of follow-up (or disease progression)
|
The time from the beginning of the patient's treatment to the occurrence and progression of the tumor
|
The last subject completes at least 24 weeks of follow-up (or disease progression)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
April 1, 2023
Primary Completion (Anticipated)
September 22, 2025
Study Completion (Anticipated)
September 22, 2025
Study Registration Dates
First Submitted
March 1, 2023
First Submitted That Met QC Criteria
March 27, 2023
First Posted (Actual)
March 30, 2023
Study Record Updates
Last Update Posted (Actual)
March 30, 2023
Last Update Submitted That Met QC Criteria
March 27, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Nasopharyngeal Neoplasms
- Carcinoma
- Nasopharyngeal Carcinoma
Other Study ID Numbers
- AK104-IIT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nasopharyngeal Carcinoma
-
National Cancer Institute (NCI)NRG OncologyTerminatedRecurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Metastatic Nasopharyngeal Nonkeratinizing Carcinoma | Metastatic Nasopharyngeal Undifferentiated Carcinoma | Nasopharyngeal... and other conditionsUnited States, Canada, China, Singapore
-
National Cancer Institute (NCI)CompletedRecurrent Nasopharynx Carcinoma | Stage III Nasopharyngeal Carcinoma AJCC v7 | Stage IV Nasopharyngeal Carcinoma AJCC v7 | Stage IVA Nasopharyngeal Carcinoma AJCC v7 | Stage IVB Nasopharyngeal Carcinoma AJCC v7 | Stage IVC Nasopharyngeal Carcinoma AJCC v7 | Nasopharyngeal Nonkeratinizing CarcinomaUnited States, Singapore, China
-
National Cancer Institute (NCI)Radiation Therapy Oncology GroupCompletedStage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7 | Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage III Nasopharyngeal...United States, Canada
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedStage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7 | Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7 | Stage II Nasopharyngeal Keratinizing... and other conditionsUnited States, Canada, Australia
-
Alain AlgaziAstraZeneca; Incyte CorporationWithdrawnRecurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma | Epstein-Barr Virus Positive | Stage III Nasopharyngeal Carcinoma | Stage IVA Nasopharyngeal Carcinoma | Stage IVB Nasopharyngeal Carcinoma
-
Alliance for Clinical Trials in OncologyNot yet recruitingRecurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownLOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE UCNTFrance
-
Stanford UniversityTerminatedStage IV Nasopharyngeal Carcinoma | Stage III Nasopharyngeal Carcinoma | Stage IVA Nasopharyngeal Carcinoma | Stage IVB Nasopharyngeal Carcinoma | Stage II Nasopharyngeal Carcinoma | Stage 0 Nasopharyngeal Carcinoma | Stage 0 Paranasal Sinus Cancer | Stage I Nasopharyngeal Carcinoma | Stage I Paranasal... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IV Nasopharyngeal Carcinoma AJCC v8 | Stage II Nasopharyngeal Carcinoma AJCC v8 | Stage III Nasopharyngeal Carcinoma AJCC v8
-
Cancer Institute and Hospital, Chinese Academy...RecruitingRecurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal CarcinomaChina
Clinical Trials on Cadonilimab
-
The First Hospital of Jilin UniversityNot yet recruiting
-
Peking University Cancer Hospital & InstituteNot yet recruitingSoft Tissue Sarcoma
-
Guangzhou Institute of Respiratory DiseaseRecruiting
-
Guangzhou Institute of Respiratory DiseaseRecruiting
-
Shanghai Pharmaceuticals Holding Co., LtdRecruiting
-
Second Affiliated Hospital of Zunyi Medical UniversityGuizhou Provincial People's Hospital; The First People's Hospital of Zunyi; Guizhou... and other collaboratorsRecruitingImmunotherapy | Second-line TreatmentChina
-
M.D. Anderson Cancer CenterRecruitingCervical Cancer | Cervix Cancer | CarcinomasUnited States
-
Tianjin Medical University Cancer Institute and...RecruitingAdvanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic TherapyChina
-
West China Second University HospitalThe Affiliated Hospital Of Southwest Medical University; Affiliated Hospital...Recruiting
-
Huazhong University of Science and TechnologyRecruiting